Prosecution Insights
Last updated: April 19, 2026
Application No. 18/655,876

METHODS OF PREPARING 1'-CYANO NUCLEOSIDES

Non-Final OA §102§103
Filed
May 06, 2024
Examiner
BERRY, LAYLA D
Art Unit
1693
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Gilead Sciences Inc.
OA Round
1 (Non-Final)
66%
Grant Probability
Favorable
1-2
OA Rounds
2y 8m
To Grant
74%
With Interview

Examiner Intelligence

Grants 66% — above average
66%
Career Allow Rate
939 granted / 1427 resolved
+5.8% vs TC avg
Moderate +9% lift
Without
With
+8.6%
Interview Lift
resolved cases with interview
Typical timeline
2y 8m
Avg Prosecution
44 currently pending
Career history
1471
Total Applications
across all art units

Statute-Specific Performance

§101
2.7%
-37.3% vs TC avg
§103
34.8%
-5.2% vs TC avg
§102
20.0%
-20.0% vs TC avg
§112
23.3%
-16.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1427 resolved cases

Office Action

§102 §103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . CONTINUING DATA This application is a DIV of 18/108,480 02/10/2023 PAT 12012431 18/108,480 is a DIV of 17/198,829 03/11/2021 PAT 11613553 17/198,829 has PRO 62/988,661 03/12/2020 Claims 59-60, 62, 64, 66, 68, 73, 75, 80-81, 83, 85-86, 89, 93, 95, 100-101, 104-105, 107, 109, 114, 117, 120, and 122 are pending. Claim Interpretation The claims recite adding input mixtures to an eighth reactor, a ninth reactor, and so on. The claims do not recite any limitations drawn to steps carried out in previous reactors, so the claims are interpreted to require adding reagents to a reactor in general regardless of its number. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 80-81, 83, 85-86, 93, 95, 114, 117, 120, and 122 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Axt (WO2016069825 A1, cited on IDS). Axt teaches the following reaction in paragraphs [0249]-[250]: PNG media_image1.png 184 737 media_image1.png Greyscale Axt teaches addition of 3.4 equivalents of 1M BCl3 in dichloromethane to a compound of claimed formula (I), followed by addition of methanol (an additive) and potassium bicarbonate to afford a compound of claimed formula (VII). Formula (I) was cooled to -20°C before addition of BCl3, and the reaction temperature was maintained between -20°C and -15°C. Axt teaches the following reaction in paragraph [0340]: PNG media_image2.png 158 724 media_image2.png Greyscale After the first reaction, the isolated solid was added to a reactor and 5% K2CO3 solution was added. The solvent in that reaction is water. Axt further teaches the following reaction in paragraph [0343]: PNG media_image3.png 161 746 media_image3.png Greyscale The reaction was carried out at 30°C. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 89 is/are rejected under 35 U.S.C. 103 as being unpatentable over Axt (WO2016069825 A1, cited on IDS). Axt teaches as set forth above, addition of methanol to prepare a compound of claimed formula (VIII). Axt does not teach that methanol is added to the Lewis acid before combining with formula (I). Methanol is added after the Lewis acid is combined with the starting compound. It would have been obvious to one of ordinary skill in the art at the time the application was filed to add methanol to the Lewis acid before addition of formula (I) instead of after. MPEP 2144.04 states that legal precedent as a source of supporting rationale for obviousness includes changes in the sequence of adding ingredients. Selection of any order of mixing ingredients is prima facie obvious. Claim(s) 59-60, 62, 64, 66, 68, 73, 75, 100-101, 104-105, 107, and 109 is/are rejected under 35 U.S.C. 103 as being unpatentable over Axt (WO2016069825 A1, cited on IDS). Axt teaches the following reaction in paragraphs [0249]-[250]: PNG media_image1.png 184 737 media_image1.png Greyscale Axt teaches addition of 3.4 equivalents of 1M BCl3 in dichloromethane to a compound of claimed formula (I), followed by addition of methanol (an additive) and potassium bicarbonate to afford a compound of claimed formula (VII). Formula (I) was cooled to -20°C before addition of BCl3, and the reaction temperature was maintained between -20°C and -15°C. The method can be carried out as a batch mode process or a flow process [0138]. Any Lewis acid can be used in the method of making Formula (XI-b) (which corresponds to claimed formula VII), including AlCl3, AlBr3, TiCl4, SnCl4, LiCl, MgCl2 [0156]. The reaction temperature can be -20°C to 0°C [0164]. Axt does not exemplify the above reaction in a flow reactor as required by claim 59 and does not exemplify the reaction using the Lewis acids recited in current claim 100. It would have been obvious to one of ordinary skill in the art at the time the application was filed to carry out Axt’s reaction of paragraphs in a flow reactor. MPEP 2144.04 stats that legal precedent as a source of supporting rationale includes making continuous. The court held that the claimed continuous operation would have been obvious in light of the batch process of the prior art. In this instance, Axt teaches a batch process and also contemplates continuous reaction, so it would have been obvious to carry out Axt’s process as a continuous process. Axt exemplifies a lower temperature for the reaction than is recited in the current claims, but it would have been obvious to one of ordinary skill in the art to optimize the temperature using routine experimentation within the broader ranges taught by Axt. MPEP 2144.05 states that "[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation." In this instance, the skilled artisan would have optimized the reaction temperature for speed and efficiency of the reaction while minimizing side products. The skilled artisan would have cooled reagents before addition in order to control the low temperature. It would have been obvious to one of ordinary skill in the art at the time the application was filed to carry out Axt’s reaction using a different Lewis acid or combination of Lewis acids because Axt teaches that any Lewis acid may be used. Simple substitution of one Lewis acid for another would have resulted in the claimed invention, and the results would have been predictable because Axt teaches that any Lewis acid may be used. Conclusion No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to LAYLA D BERRY whose telephone number is (571)272-9572. The examiner can normally be reached 7:00-3:00 CST, M-F. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Scarlett Goon can be reached at 571-270-5241. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /LAYLA D BERRY/Primary Examiner, Art Unit 1693
Read full office action

Prosecution Timeline

May 06, 2024
Application Filed
Feb 17, 2026
Non-Final Rejection — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12594289
POTENTIATION OF ANTIBIOTIC EFFECT
2y 5m to grant Granted Apr 07, 2026
Patent 12595508
NUCLEOTIDE CLEAVABLE LINKERS AND USES THEREOF
2y 5m to grant Granted Apr 07, 2026
Patent 12589110
CARBONATED AEROSOL EXTERNAL PREPARATION FOR SKIN
2y 5m to grant Granted Mar 31, 2026
Patent 12583883
ASYMMETRIC AUXILIARY GROUP
2y 5m to grant Granted Mar 24, 2026
Patent 12577269
CONTINUOUS PROCESS FOR PREPARING THE CRYSTALLINE FORM II OF SOTAGLIFLOZIN
2y 5m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
66%
Grant Probability
74%
With Interview (+8.6%)
2y 8m
Median Time to Grant
Low
PTA Risk
Based on 1427 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month